Showing results (81-90 of 172) with videos related to
Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study databasePhilippe Solal-Céligny, Monica Bellei, Luigi Marcheselli, et al.British Journal of Haematology|March 2, 2019
Long-term overall- and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphomaTamer Khashab, Fredrick Hagemeister, Jorge E Romaguera, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2012
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II studyBarbara Pro, Ranjana Advani, Pauline Brice, et al.JCO Oncology Practice|December 6, 2024
Comparison of Survivorship Care Guidelines for Patients With Lymphoma: Recommendations for Harmonization and Future Research AgendaBryan Valcarcel, Kerry J Savage, Brian K Link, et al.British Journal of Haematology|August 26, 2010
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphomaJorge E Romaguera, Luis E Fayad, Peter McLaughlin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's diseaseAnas Younes, Barbara Pro, Michael J Robertson, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|February 6, 2015
Comparison of survival in patients with T cell lymphoma after autologous and allogeneic stem cell transplantation as a frontline strategy or in relapsed diseaseAmer Beitinjaneh, Rima M Saliba, L Jeffrey Medeiros, et al.Journal of the American Academy of Dermatology|January 9, 2018
Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapyMaria Estela Martinez-Escala, Alba L Posligua, Heather Wickless, et al.Leukemia & Lymphoma|August 2, 2021
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomasWilliam B Pearse, Adam M Petrich, Leo I Gordon, et al.Blood Advances|September 27, 2023
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphomaReem Karmali, Jeremy S Abramson, Deborah M Stephens, et al.Pageof 18